Influx Healthtech Ltd vs Remus Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Influx Healthtech Ltd is ₹ 280.5 as of 18 May 15:30 . The P/E Ratio of Influx Healthtech Ltd is 0 as of March 2024 .The P/E Ratio of Remus Pharmaceuticals Ltd is 49.4 as of March 2024 . The Market Cap of Influx Healthtech Ltd is ₹ 0 crore as of March 2024 .The Market Cap of Remus Pharmaceuticals Ltd is ₹ 1016 crore as of March 2024 . The Dividend Payout of Influx Healthtech Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Remus Pharmaceuticals Ltd changed from 2.56 % on March 2023 to 4.44 % on March 2025 . This represents a CAGR of 20.15% over 3 years .

About Influx Healthtech Ltd

Influx Healthtech Limited was originally incorporated on September 28, 2020 as a Private Limited Company as 'Influx Healthtech Private Limited' with the Registrar of Companies, Central Registration Centre.
Company converted from a Private Limited to Public Limited and the name of Company was changed to Influx Healthtech Limited' and a Fresh Certificate of Incorporation upon the conversion was issued on May 23, 2022 by the Registrar of Companies, Mumbai. Influx Healthtech Limited is a a Mumbai-based healthcare product-focused company that has carved a niche in manufacturing Soft Gelatin, Tablets, Capsules, Liquid Orals, Oral Powders, Liquid fill capsules, Effervescent tablets, Nutra Pallets, Protein Bars, Cookies, Jellies/ Gummies, External preparations like Creams, Gels, Ointments, External Oils, Soaps, etc.

About Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat.
Subsequently, Company converted from a Private to Public and the name of the Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad. The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs.
It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

FAQs for the comparison of Influx Healthtech Ltd and Remus Pharmaceuticals Ltd

Which company has a larger market capitalization, Influx Healthtech Ltd or Remus Pharmaceuticals Ltd?

Market cap of Influx Healthtech Ltd is 672 Cr while Market cap of Remus Pharmaceuticals Ltd is 1,019 Cr

What are the key factors driving the stock performance of Influx Healthtech Ltd and Remus Pharmaceuticals Ltd?

The stock performance of Influx Healthtech Ltd and Remus Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Influx Healthtech Ltd and Remus Pharmaceuticals Ltd?

As of May 18, 2026, the Influx Healthtech Ltd stock price is INR ₹290.5. On the other hand, Remus Pharmaceuticals Ltd stock price is INR ₹865.25.

How do dividend payouts of Influx Healthtech Ltd and Remus Pharmaceuticals Ltd compare?

To compare the dividend payouts of Influx Healthtech Ltd and Remus Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.